Shailaja joined Engitix in March 2026 as VP, Head of CMC.

With over 20 years of experience across both small and large pharmaceutical companies, Shailaja brings deep expertise in Chemistry, Manufacturing, and Controls (CMC) aspects of drug development.

Shailaja joins Engitix from Eli Lilly, where she was responsible for CMC drug product development and manufacturing for early-stage oncology programs, including multiple ADC programs. Previously, she held leadership roles at Greenfire Bio, Takeda, and Johnson & Johnson. She has authored multiple clinical trial applications and BLAs, including Sylvant™ and Darzalex.

Shailaja earned her PhD from the University of Connecticut and is a recognised expert in lyophilisation.

‍

‍